Hims & Hins sees the legislator checked
Hims & Hein Before examining the legislator on an advertisement for its weight loss offers, which should run on Sunday during the Super Bowl.
Sens. Dick Durbin, D-ILL., And Roger Marshall, R-Kan. Information in promoting a certain type of weight loss medication. “
The HIMS & HERS display that the company published online at the end of January is called “Sank of the System” and criticizes the weight loss industry in the amount of $ 160 billion. It shows the graphics of existing weight loss medication Novo Nordisks Blockbuster Diabetes Drug Ozempic.
The AD claims that these drugs are “for profits, not for patients” and refers to HIMS & HERS ‘weight loss medication as “affordable” and “medically familiar” alternatives.
“We adhere to the existing right and look forward to continuing to work with the congress and the new administration in order to remedy and ensure the broken health system.
The senators do not mention him in their letter, but they refer to some of the visuals in the advertisement, including “pictures of an injection foundation with distinctive properties that reflect an existing brand medication”.
“Nowhere in this campaign is there a disclosure, risk or security information of side effects, as would normally be necessary in a pharmaceutical advertising,” wrote the senators. “In addition, only three seconds flashes in the tiny commercial of the screen in small, barely readable font that these products are not approved by the FDA.”
Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said on Friday that the HIMS & HERS advertisement matches the “auxiliary seeking” pharmaceutical advertising.
“The Super Bowl display from HIMS does not promote a certain medication or medication and is therefore not necessary to provide information about side effects or risks,” said Brunner in an explanation. “Instead, it encouraged the audience to advise themselves with a health service provider who matches the guidelines of the FTC for non -specific, help seeking ads.”
Hims & Hers started offering a new Semaglutide in May after starting a new weight loss program at the end of 2023. Semaglutid is the active ingredient in Ozempic and Wegovy, which can cost around $ 1,000 per month without insurance.
The shares of HIMS & HIS rose by more than 170% last year, thanks to the increasing demand for GLP-1S. They closed 5% on Friday and raised the company’s market capitalization to around 9.5 billion US dollars.
COMPLESS GLP-1S are usually much cheaper and can serve as an alternative for patients who navigate complex supply hurdles and spotty insurance coverage insurance. HIMS & HINS sells Semaglutide for less than 200 US dollars per month.
The FDA does not check the safety and effectiveness of compiled products that are tailor -made alternatives to branded medication that meet the needs of a specific patient. Compiled products can also be manufactured if the brand treatments are lacking.
According to the FDA, Semaglutid is currently poor.
According to Durbin and Marshall, advertising for branded medication for the brand name “significant risk information for patients about side effects and contraindications, including warnings of potential gallbladder, pancreas, vomiting, diarrhea and other implications.”
A publication on Durbin’s website states that the display in question seems to use a gap in relation to advertising actions of increased drugs by telemedicine companies “.
The senators said that the FDA may have the authority to take enforcement measures against marketing that could mislead patients and plan to introduce new laws to combat regulatory gaps.
REGARD: New study shows why patients stop taking GLP-1 fatty migration medication
